Sector News

Major policy shift on costs and safety views as China moves to lift price controls on drugs

March 5, 2015
Life sciences
China Premier Li Keqiang said the government will lift price controls on pharmaceuticals, which would mark a dramatic change of tack in efforts to both widen access to medicines from the cities into the countryside while keeping spending in check.
 
Li announced the decision in his annual government work report plan that opens the annual two-week National People’s Conference, a legislative body that nominally advises the Communist Party-run government on broad policy aims.
 
The report did not disclose details or a timeline. The disclosure is part of a broad statement on China’s intention to eventually lift price controls and give market forces a greater role in its economy.
 
“In principle, we will lift pricing controls over all goods and services that can viably compete in markets,” it said. “The government will stop setting prices for most pharmaceuticals and delegate to lower-level governments the power to set prices for certain basic public services.”
 
China wants to develop the domestic pharmaceutical industry through stronger regulatory measures and has moved in the past two years of the government of Xi Jinping to form a China FDA based on a U.S. model that has issued mandatory requirements to be certified in good manufacturing practices and similar rules aimed at overcoming widespread public concern, and anger, about product safety.
 
At the same time however, the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients, distorting market incentives that some analysts say lead to safety lapses and inappropriate prescriptions.
 
Pharmaceuticals account for about half of total health spending in China, representing 43% of spending per inpatient episode and 51% of spending per outpatient visit, according to government figures.
 
Analysts also say the move is part of a broader drug reform in which the government plans to sell drugs online, shaking up the procurement system entirely and creating a more transparent system.
 
The aim is to solve problems that have plagued hospital pharmacies. Drug sales make up more than 80% of hospital revenue, according to consulting firm Bain & Co.
 
By EJ Lane
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).